BCM
SRPT icon

Beck Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Beck Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-33,999
Closed -$492K – 149
2014
Q4 		$492K Buy
33,999
+7,745
+30% +$131K 0.29% 84
2014
Q3 		$521K Sell
26,254
-2,190
-8% -$49.4K 0.37% 81
2014
Q2 		$847K Buy
28,444
+3,700
+15% +$117K 0.56% 58
2014
Q1 		$636K Buy
24,744
+2,385
+11% +$60.8K 0.49% 76
2013
Q4 		$543K Buy
+22,359
New +$664K 0.44% 77

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Beck Capital Management's SRPT Position: Q1 2015 in Review

Beck Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2015, closing a stake of 33,999 shares — an estimated $492K sold.

Beck Capital Management first reported a position in SRPT in Q4 2013 and held it in 5 quarters. The position peaked at $847K in Q2 2014. 114 funds tracked by Wall St. Rank hold SRPT as of Q1 2015.

  • Beck Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Beck Capital Management sold 33,999 Sarepta Therapeutics shares in Q1 2015, an estimated $492K.
  • Beck Capital Management first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 5 quarters.
  • Beck Capital Management's Sarepta Therapeutics position peaked at $847K in Q2 2014.
  • 114 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2015.

Based on Beck Capital Management's 13F filing for Q1 2015, filed 14 May 2015.